MedTrace Logo

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

NCT04491006 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2023-06-12

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.

Conditions

  • Alzheimer Disease
  • Dementia of Alzheimer Type

Interventions

DRUG

ATH-1017

Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe

DRUG

Placebo

Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Athira Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-23
Primary Completion
2022-05-20
Completion
2022-05-20
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04491006 on ClinicalTrials.gov